Natural history and treatment effects in Guillain-Barré syndrome: a multicentre study
- PMID: 8669925
- PMCID: PMC1511471
- DOI: 10.1136/adc.74.4.281
Natural history and treatment effects in Guillain-Barré syndrome: a multicentre study
Abstract
A retrospective multicentre study was performed to investigate the natural history and treatment effects in childhood Guillain-Barré syndrome in a large number of patients. Structured questionnaires were sent to 155 paediatric hospitals for details of patients who conformed to internationally accepted diagnostic criteria and who were treated from spring 1989 to summer 1994. Sixty nine hospitals reported data of 175 patients aged 11 months to 17.7 years. At the height of the disease 26% of the patients remained able to walk, but 16% had to be artificially ventilated. The median time from onset of symptoms to first recovery was 17 days, to walk unaided 37 days, and to be free of symptoms 66 days. There was a large group with a benign and a smaller one with a more protracted course. At long term follow up, 98/106 patients were free of symptoms and the remainder were able to walk unaided. Maximum disability grade was the most powerful prognostic factor. In children unable to walk but not yet tetraplegic, immunoglobulins were able to accelerate recovery. Corticosteroids were less potent. Plasmapheresis could not be evaluated because it was administered only in the most severe cases. The natural history of Guillain-Barré syndrome in children is extremely variable and more benign than in adults. Treatment with immunoglobulins should be considered in patients unable to walk. Corticosteroids are not as effective and should be withheld except when, in protracted courses, suspicion of chronic inflammatory demyelinating polyneuropathy arises.
Similar articles
-
Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome.Scand J Infect Dis. 1995;27(3):241-3. doi: 10.3109/00365549509019016. Scand J Infect Dis. 1995. PMID: 8539548 Clinical Trial.
-
Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial.Pediatrics. 2005 Jul;116(1):8-14. doi: 10.1542/peds.2004-1324. Pediatrics. 2005. PMID: 15995024 Clinical Trial.
-
Guillain-Barré syndrome in childhood: natural course and efficacy of plasmapheresis.Pediatr Neurol. 1993 Jan-Feb;9(1):16-20. doi: 10.1016/0887-8994(93)90004-v. Pediatr Neurol. 1993. PMID: 8452594
-
Childhood acute and chronic immune-mediated polyradiculoneuropathies.Eur J Paediatr Neurol. 2009 May;13(3):209-18. doi: 10.1016/j.ejpn.2008.04.009. Epub 2008 Jun 26. Eur J Paediatr Neurol. 2009. PMID: 18585069 Review.
-
Intravenous immunoglobulin as therapy for pediatric Guillain-Barré syndrome.J Child Neurol. 1997 Sep;12(6):376-80. doi: 10.1177/088307389701200607. J Child Neurol. 1997. PMID: 9309521 Review.
Cited by
-
Guillain-Barré syndrome.Postgrad Med J. 2000 Dec;76(902):774-82. doi: 10.1136/pmj.76.902.774. Postgrad Med J. 2000. PMID: 11085768 Free PMC article. Review.
-
Prospective study of children with Guillain-Barre syndrome.Indian J Pediatr. 2008 Aug;75(8):787-90. doi: 10.1007/s12098-008-0099-1. Epub 2008 Jun 25. Indian J Pediatr. 2008. PMID: 18581067
-
Effects of robot exoskeletal-assisted gait training on gait ability in a pediatric patient with peripheral polyneuropathy: a case report.J Phys Ther Sci. 2024 Sep;36(9):583-587. doi: 10.1589/jpts.36.583. Epub 2024 Sep 5. J Phys Ther Sci. 2024. PMID: 39239406 Free PMC article.
-
Exchange transfusion as an alternative therapy for recurrent severe Guillain-Barre syndrome.Indian J Pediatr. 2007 Jul;74(7):689-91. doi: 10.1007/s12098-007-0122-y. Indian J Pediatr. 2007. PMID: 17699980
-
Guillain-Barré syndrome in children.Neurol Sci. 2011 Jun;32(3):381-5. doi: 10.1007/s10072-010-0434-y. Epub 2010 Oct 16. Neurol Sci. 2011. PMID: 20953812
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources